Glioblastoma in adults

被引:148
作者
Brandes, Alba A. [1 ]
Tosoni, Alicia [1 ]
Franceschi, Enrico [1 ]
Reni, Michele [2 ]
Gatta, Gernma [3 ]
Vecht, Charles [4 ]
机构
[1] Azienda ASL, Bellaria Maggiore Hosp, Dept Med Oncol, Bologna, Italy
[2] Ist Sci San Raffaele, Med Oncol Unit, I-20132 Milan, Italy
[3] Ist Nazl Tumori, Fdn IRCCS, I-20133 Milan, Italy
[4] Neurol Med Ctr, The Hague, Netherlands
关键词
glioblastoma; radiotherapy; chemotherapy; review;
D O I
10.1016/j.critrevonc.2008.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis'. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors. Surgery aimed to complete resection should be the first therapeutic modality in the management of glioblastoma. However, complete resection is virtually impossible due to infiltrative nature of this disease and relapse is almost inevitable. Postoperative concomitant chemo-radiation is the standard treatment and consists of 60 Gy of external-beam radiotherapy (to be delivered to a target volume including a 2-3 cm ring of tissue surrounding the perimeter of the contrast enhancing lesion on pre-operative CT/MRI scans) plus temozolomide (TMZ) administered concomitantly (75 mg/m(2) daily) and after radiotherapy (150-200 mg/m(2), for 5 days every 4 weeks). At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:139 / 152
页数:14
相关论文
共 106 条
[1]   COMBINED RADIOTHERAPY AND CHEMOTHERAPY WITH DIBROMODULCITOL AND CCNU IN THE POSTOPERATIVE TREATMENT OF MALIGNANT GLIOMAS [J].
AFRA, D ;
KOCSIS, B ;
DOBAY, J ;
ECKHARDT, S .
JOURNAL OF NEUROSURGERY, 1983, 59 (01) :106-110
[2]  
Afra D, 2002, LANCET, V359, P1011
[3]  
Aldape K, 2000, CANCER-AM CANCER SOC, V88, P2342, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO
[4]  
2-X
[5]  
BAKER F, 1996, P ASCO
[6]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[7]   Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse [J].
Brada, M ;
Hoang-Xuan, K ;
Rampling, R ;
Dietrich, PY ;
Dirix, LY ;
Macdonald, D ;
Heimans, JJ ;
Zonnenberg, BA ;
Bravo-Marques, JM ;
Henriksson, R ;
Stupp, R ;
Yue, N ;
Bruner, J ;
Dugan, M ;
Rao, S ;
Zaknoen, S .
ANNALS OF ONCOLOGY, 2001, 12 (02) :259-266
[8]  
Brada M, 1999, FRONT RADIAT THER ON, V33, P139
[9]   Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) [J].
Brandes, A. A. ;
Tosoni, A. ;
Cavallo, G. ;
Bertorelle, R. ;
Gioia, V. ;
Franceschi, E. ;
Biscuola, M. ;
Blatt, V. ;
Crino, L. ;
Ermani, M. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1155-1160
[10]   The role of chemotherapy in recurrent malignant gliomas: An overview [J].
Brandes, AA ;
Fiorentino, MV .
CANCER INVESTIGATION, 1996, 14 (06) :551-558